Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK, Theravance develop respiratory drug candidates

Executive Summary

GlaxoSmithKline and Theravance (small-molecule drug discovery technologies) entered an agreement to develop and sell respiratory disease therapeutics, including those for asthma and chronic obstructive pulmonary disease. The deal could be worth up to £245.2mm ($395mm) to Theravance.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register